U.S. markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.06 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,812.50
    -18.70 (-1.02%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1871
    -0.0025 (-0.21%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • GBP/USD

    1.3906
    -0.0051 (-0.37%)
     
  • USD/JPY

    109.6150
    +0.1540 (+0.14%)
     
  • BTC-USD

    41,986.86
    +1,995.83 (+4.99%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

U.S. court grants exclusivity for Amarin's Vascepa

May 28 (Reuters) - A U.S. district court has ruled that Amarin Corp's fish oil pill, Vascepa, is eligible for five years of marketing exclusivity, setting aside a U.S. Food and Drug administration decision.

Amarin's shares rose as much as 44 percent to $2.80 on the Nasdaq. The stock was trading up 19 percent at $2.33 on Thursday afternoon.

Vascepa was approved in 2012 to reduce high levels of blood fat called triglycerides in patients not using cholesterol-lowering statins.

The case is Amarin v. U.S. FDA and HHS, U.S. District Court for the District of Columbia, No. 14-cv-00324. (http://1.usa.gov/1QdfHeC) (Reporting by Natalie Grover and Ankur Banerjee in Bengaluru; Editing by Don Sebastian)